- Home
- GDTC vs NCNA Comparison
GDTC vs NCNA Comparison
Compare GDTC & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDTC | NCNA |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 13.8M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GDTC | NCNA |
|---|---|---|
| Price | $1.02 | $2.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 173.3K | 90.2K |
| Earning Date | 04-24-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $573,193.00 | N/A |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.03 | N/A |
| 52 Week Low | $0.73 | $2.28 |
| 52 Week High | $3.68 | $268.00 |
Technical Indicators
Market Signals| Indicator | GDTC | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 21.69 |
| Support Level | $0.80 | $2.89 |
| Resistance Level | $0.90 | $2.67 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 73.89 | 5.93 |
Price Performance
Historical ComparisonAbout GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.